bluebird bio

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Bluebird bio reports strong financials and plans for expansion

Bluebird bio demonstrated financial strength and successful gene therapy launches.
Challenges include potential submission delay and operational complexities.
Opportunities lie in expanding patient demand, optimizing strategies, and exploring international markets.
Overall, Bluebird bio remains confident in its products and market positioning.

Bluebird bio excels in gene therapy market, faces manufacturing challenges

Bluebird bio is making significant strides in gene therapy, with successful commercial launches and a strong financial position.
Challenges lie in adapting to a different manufacturing process for lovo-cel and ensuring operational efficiency for future launches.
Opportunities abound in expanding commercial reach, leveraging expertise for targeted launches, and strategic decision-making on PRV monetization.

Bluebird bio reports revenue growth and milestones in Q3

Bluebird bio's Q3 performance showed revenue growth and positive momentum in key product launches.
The company faces challenges related to safety concerns, manufacturing issues, and analyst inquiries.
Strengths lie in a well-established commercial infrastructure and strategic pricing approach.
Opportunities include financing plans, potential voucher sale, and expansion of treatment centers.

bluebird bio reports revenue growth and eyes U.S. expansion opportunities

bluebird bio's Q4 performance showed revenue growth and extended cash runway
Strengths lie in commercial progress, multibillion-dollar U.S. opportunity, and margin improvement
Challenges include financial restatement, reimbursement dynamics, and Medicaid coverage
Opportunities exist in ex U.S. markets, expansion plans, and optimizing reimbursement strategies

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it received notices (the “notices”) on August 20, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Reports on Form 10-Q for each of the quarters ended March 31, 2024 (the “Q1 2024 Form 10-Q”) and June 30, 2024 (the “Q2 2024 Form 10-Q”), it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires listed companies.

bluebird bio Announces Receipt of Expected Notices from Nasdaq

bluebird bio, Inc. (NASDAQ:BLUE ) Q2 2024 Results Conference Call August 14, 2024 8:00 AM ET Company Participants Courtney O'Leary - Director of Investor Relations Andrew Obenshain - CEO Tom Klima - Chief Commercial and Operating Officer James Sterling - CFO Conference Call Participants Jack Allen - Baird Eric Joseph - JPMorgan Gena Wang - Barclays Jeff Hung - Morgan Stanley Luca Issi - RBC Capital Markets Sami Corwin - William Blair Operator Thank you for standing by. My name is Ken and I will be your conference operator today.

bluebird bio, Inc. (BLUE) Q2 2024 Earnings Call Transcript

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported second quarter results and business highlights for the quarter ended June 30, 2024, including recent commercial and operational progress. “We are seeing clear evidence that our commercial launch is accelerating, with over 20 cell collections completed in sickle cell disease and beta-thalassemia to date in 2024, and more than 40 additional patients already scheduled to initiate.

bluebird bio Reports Second Quarter 2024 Results and Highlights Operational Progress and 2024 Guidance

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14, at 8:00 a.m. ET. To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and ask to be joined into the bluebird call or provide the Conference ID 2776050. To access the live webcast, please visit the “Events & Presentations” page within the Investors & Media secti.

bluebird bio Announces Second Quarter 2024 Results Call Date

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 38,200 shares of common stock to its controller and vice president of accounting, Joe Ewer, with a grant date of August 1, 2024. The stock options approved under the Inducement Plan have an exercise price per share equal to $1.08, the fair market value of the Company's common.

bluebird bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Bluebird bio Inc. (NASDAQ: BLUE) on behalf of long-term stockholders following a class action complaint that was filed against Blue on March 28, 2024 with a Class Period from April 24, 2023 to December 8, 2023. Our investigation concerns whether the board of directors of Blue have breached their fiduciary duties to the company.

BLUE ALERT: Bragar Eagel & Squire, P.C. is Investigating Bluebird bio Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved an inducement grant of stock options to purchase a total of 300,000 shares of common stock to its chief financial officer, James Sterling, with a grant date of July 1, 2024. The stock options approved under the Inducement Plan have an exercise price per share equal to $0.98, the fair market value of the Company's common stock on the g.

bluebird bio Reports Inducement Grant to CFO James Sterling Under Nasdaq Listing Rule 5635(c)(4)

Amgen

Bristol-Myers

Gilead Sciences

Neurocrine Biosciences

Novartis

Ultragenyx Pharmaceutical

Biotech stocks operate under a core ethos. While there's been much talk about financially viable sectors – from tech to cryptocurrencies to even precious metals – when you think about it, nothing is more valuable than one's health.

7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline

CHICAGO , June 2, 2024 /PRNewswire/ -- 2Flo Ventures, an emerging venture capital firm and startup studio focused on the discovery, development, and commercialization of healthcare solutions that address disparities in outcomes and health equity broadly, is pleased to announce the addition of Dr. Charlotte Jones-Burton  as a Partner and Head of Life Science Product Development and Strategy. 2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner Dr. Jones-Burton brings to 2Flo Ventures nearly two decades of experience in the biopharmaceutical industry leading clinical development of multiple medicines across various therapeutic areas.

2Flo Ventures Announces Addition of Renowned Life Sciences Executive Charlotte Jones-Burton, MD, MS as a Partner

Gene therapy maker bluebird bio on Wednesday named former Renalytix finance chief James Sterling as its CFO to oversee the revision of the company's financial statements.

Bluebird bio appoints new CFO to oversee financial restatements

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that O. James Sterling, has been appointed chief financial officer (CFO), effective June 10, 2024. Mr. Sterling most recently served as chief financial officer of Renalytix plc, a diagnostics company focused on clinical management of kidney disease. “We are thrilled to welcome James to bluebird bio. We are confident that his extensive experience in the healthcare sector and knowledge of the capital markets wil.

bluebird bio Appoints O. James Sterling as Chief Financial Officer

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming May 28, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) common stock between April 24, 2023 and December 8, 2023, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On December 8, 2023, bluebird announced that it had receive.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

NEW YORK , May 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in bluebird bio, Inc. ("bluebird bio" or the "Company") (NASDAQ: BLUE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of bluebird bio investors who were adversely affected by alleged securities fraud between April 24, 2023 and December 8, 2023.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 28, 2024 in bluebird bio Lawsuit - BLUE

NEW YORK , May 22, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against bluebird bio, Inc. ("bluebird" or the "Company") (NASDAQ: BLUE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against bluebird bio, Inc. - BLUE

BENSALEM, Pa. , May 22, 2024 /PRNewswire/ -- Law Offices of Howard G.

BLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud Lawsuit

NEW YORK , May 21, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of bluebird bio, Inc. (NASDAQ: BLUE). Shareholders who purchased shares of BLUE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

Investors in bluebird bio, Inc. Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUE

NEW YORK, NY / ACCESSWIRE / May 20, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80686&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUE

NEW YORK, NY / ACCESSWIRE / May 20, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80689&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on bluebird bio, Inc. (BLUE) should contact Levi & Korsinsky about pending Class Action - BLUE

NEW YORK, NY / ACCESSWIRE / May 19, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80646&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

NEW YORK, NY / ACCESSWIRE / May 19, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80639&wire=1 or contact Joseph E. Levi, Esq.

Shareholders of bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUE

LOS ANGELES, CA / ACCESSWIRE / May 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 28, 2024.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 19, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80601&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies Shareholders of bluebird bio, Inc.(BLUE) of a Class Action Lawsuit and an Upcoming Deadline

NEW YORK, NY / ACCESSWIRE / May 18, 2024 / If you suffered a loss on your bluebird bio, Inc. (NASDAQ:BLUE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/bluebird-bio-lawsuit-submission-form?prid=80574&wire=1 or contact Joseph E. Levi, Esq.

Investors in bluebird bio, Inc. Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUE

LOS ANGELES, CA / ACCESSWIRE / May 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against bluebird bio, Inc. ("bluebird" or "the Company") (NASDAQ:BLUE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 24, 2023 and December 8, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before May 28, 2024.

IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Encourages Investors in bluebird bio, Inc. with Losses of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Investigation--The law firm of Kirby McInerney LLP reminds investors of the May 28, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed on behalf of those who acquired bluebird bio, Inc. (“Blue” or the “Company”) (NASDAQ: BLUE) securities during the period of April 24, 2023 through December 8, 2023, inclusive (“the Class Period”). [Click here to learn more about the class action] On December 8, 2023, Blue announced that the Unite.

News for bluebird bio Stock (BLUE)